{"id":"artesunate-for-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Artesunate is a derivative of artemisinin, a compound found in the herb Artemisia annua. It targets the malaria parasite's plasmodial protein, disrupting its ability to synthesize ATP and ultimately leading to the parasite's death.","oneSentence":"Artesunate for Injection works by inhibiting the growth of malaria parasites in the blood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:23.832Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of severe malaria"},{"name":"Treatment of uncomplicated malaria"}]},"trialDetails":[{"nctId":"NCT06806956","phase":"","title":"Severe Malaria in Remote Areas- Closing the Evidence Gap","status":"ENROLLING_BY_INVITATION","sponsor":"Tropical Diseases Research Centre, Zambia","startDate":"2024-03-10","conditions":"Severe Malaria","enrollment":2016},{"nctId":"NCT06853184","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Artesunate","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2025-08-01","conditions":"CMV Infection","enrollment":90},{"nctId":"NCT06555809","phase":"","title":"Evaluation of Artesunate in Infants Being Treated for Severe Malaria","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2024-10-06","conditions":"Malaria","enrollment":15},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT05140278","phase":"PHASE2","title":"Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-18","conditions":"Severe Malaria","enrollment":200},{"nctId":"NCT02786589","phase":"PHASE1, PHASE2","title":"Plasmodium Immunotherapy for Lung Cancer","status":"UNKNOWN","sponsor":"State Key Laboratory of Respiratory Disease","startDate":"2016-06-27","conditions":"Lung Cancer, Nonsmall Cell","enrollment":30},{"nctId":"NCT05273242","phase":"PHASE4","title":"Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal","status":"UNKNOWN","sponsor":"Nepal Health Research Council","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT03083847","phase":"PHASE1","title":"Dose Escalation PfSPZ-CVac","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-05","conditions":"Malaria","enrollment":55},{"nctId":"NCT02627456","phase":"PHASE1","title":"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-09","conditions":"Malaria","enrollment":409},{"nctId":"NCT01955382","phase":"PHASE2","title":"Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09","conditions":"Malaria, Severe Malaria","enrollment":70},{"nctId":"NCT02563704","phase":"PHASE3","title":"A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon","status":"COMPLETED","sponsor":"University of Yaounde 1","startDate":"2013-09","conditions":"Malaria","enrollment":238},{"nctId":"NCT01828333","phase":"","title":"Malaria Treatment With Injectable ArteSunate","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2013-04","conditions":"Severe Malaria","enrollment":350},{"nctId":"NCT00459615","phase":"PHASE2","title":"Phase II Dose Ranging Study of Artesunate","status":"COMPLETED","sponsor":"U.S. Army Office of the Surgeon General","startDate":"2007-04","conditions":"Falciparum Malaria, Uncomplicated Malaria","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Artesunate for Injection","genericName":"Artesunate for Injection","companyName":"U.S. Army Office of the Surgeon General","companyId":"u-s-army-office-of-the-surgeon-general","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate for Injection works by inhibiting the growth of malaria parasites in the blood. Used for Treatment of severe malaria, Treatment of uncomplicated malaria.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}